AlloVir cuts staff 95% after phase 3 failures

Today’s Big News

Jan 5, 2024

Doudna's Intellia, Zhang's Aera the latest gene editing biotechs to lay off staff 


After Pfizer's exit, UCB splits from industry trade group BIO 


Reeling from triple phase 3 failure, AlloVir cuts 95% of workforce 


Medtronic claims European approval for its latest leadless pacemaker implants


Study finds no link between Novo Nordisk’s GLP-1 drugs and suicidal ideation


Boehringer Ingelheim deals thrice, ending week with $449M Kyowa Kirin tie up

 

Featured

Doudna's Intellia, Zhang's Aera the latest gene editing biotechs to lay off staff

Intellia Therapeutics is the latest gene editing biotech to downsize following a dismal year for the industry.
 

Top Stories

After Pfizer's exit, UCB splits from industry trade group BIO

Both companies opted not to renew their 2024 memberships with the Biotechnology Innovation Organization (BIO). UCB will still retain its membership in other top trade groups, including the Pharmaceutical Research and Manufacturers Association of America (PhRMA).

Reeling from triple phase 3 failure, AlloVir cuts 95% of workforce

Less than a month after AlloVir suffered a triple phase 3 failure, the allogeneic T cell immunotherapy biotech is cutting 95% of its workforce.

Medtronic claims European approval for its latest leadless pacemaker implants

The CE mark covers the Micra AV2 and VR2 cardiac implants, which the medtech giant describes as the world’s smallest.

Study finds no link between Novo Nordisk’s GLP-1 drugs and suicidal ideation

Three days after the FDA included Novo Nordisk’s semaglutide treatments Ozempic and Wegovy on a list of medicines that it would monitor for side effects—one of them suicide ideation—a study of medical records of patients shows no link between use of the GLP-1 drugs and an increase in suicidal thoughts. In fact, the research shows that those who were on semaglutide were less likely to have suicidal thoughts than patients on other diabetes and obesity meds.

Boehringer Ingelheim deals thrice, ending week with $449M Kyowa Kirin tie up

Apparently thrice is nice for Boehringer Ingelheim, which has now announced a trio of deals this week. Friday’s tie-up involves €410 million ($449 million) for Kyowa Kirin to work on fibro-inflammatory diseases.

IQVIA, DeepIntent in ‘incredibly difficult moment’ abandon merger amid FTC scrutiny

The attempted merger between leading biopharma data provider IQVIA and pharma ad specialist DeepIntent has been put on ice after continued scrutiny from the U.S. government.

Thermo Fisher to cut the lights at California plastics plant, lay off 74

The Petaluma, CA facility produced disposable plastics and expanded in 2020 to keep up with COVID testing demands. Now, the site will shut down in July.

FDA issues Class I recall label to Insulet’s Omnipod Android app over incorrect bolus calculations

The FDA has handed down a Class I recall label, the agency’s most serious, to a now-corrected software issue that could have resulted in delivering ten times the desired insulin dose from Insulet’s Omnipod 5 automated pump.

Allogene makes ‘bold’ pivot, stopping pivotal trials in pursuit of first-line CAR-T cures

Nobody can accuse Allogene Therapeutics of lacking confidence. Believing that its CAR-T can boost cure rates, and thereby potentially make later-line treatment “obsolete,” the biotech has stopped two trials in advanced lymphoma patients to focus on a new study in people with minimal residual disease (MRD).

Beleaguered Theravance logs head-to-head trial loss for Yupelri against Boehringer's Spiriva

In the phase 4 study, Theravance and Viatris’ Yupelri failed to demonstrate greater lung function improvement in adults with COPD versus Spiriva delivered by a dry powder inhaler, Theravance said Friday.

CureVac touts COVID-19 vax data as platform validation, despite grade 3 adverse events

CureVac says its monovalent and bivalent COVID-19 vaccine candidates produced meaningful immune responses at lower doses than similar approved vaccines and were generally safe—though grade 3 adverse events were recorded in the mid-stage trial. 
 
Fierce podcasts

Don’t miss an episode

'The Top Line': The year in biotech

This week on "The Top Line," Fierce Biotech staff writer Gabrielle Masson and senior editor Annalee Armstrong look back at the year in biotech, which was defined by massive layoffs across the industry. They also discuss their favorite stories of the year, including an appearance from a popstar whose reputation precedes her.
 

Resources

Whitepaper

Digital Health Innovation: From Concept to Commercialization

The road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process.
Whitepaper

Developing and Manufacturing Drugs with HPAPIs

Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient.
eBook

7 “Make or Break” Factors for Emerging Biopharma Companies

This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products.  It’s an essential resource for emerging companies with products in all stages of development.
 

Whitepaper

Quantify microbial biomarkers with high sensitivity and dynamic range

qPCR Assay Design - Quantify microbial biomarkers with high sensitivity and dynamic range
Whitepaper

Pathway to GMP Expectations for Gene-Modified Cell Therapies

Streamline your clinical cell therapy with our GMP-compliant ribonucleoprotein (RNP) manufacturing as you scale up without compromising on quality to tackle complex regulatory requirements.
Whitepaper

Expedite Drug Discovery and Run Fewer Clinical Trials With High Performance Computing and Artificial Intelligence

High performance computing (HPC) combined with artificial intelligence (AI) and machine learning (ML) can speed up research and development processes and dramatically reduce reliance on expensive clinical trials. Download the free solution brief to learn more.

Whitepaper

Fed-Batch Intensification To Increase Titer In Biologics Manufacturing

Improving efficiency and productivity in biologics manufacturing is a longstanding goal within today’s industry, especially now as new and increasingly complex molecules are fundamentally changing technological and operational approaches to drug development. Process intensification can help accelerate this pace of innovation through advanced process development techniques and high productivity manufacturing platforms.

Whitepaper

Effective Technology Transfers for Mammalian-Derived Biologics

As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. 

 

Industry Events

 

Upcoming Fierce Events

9-10
Jan
San Francisco, CA
16-18
Jan
Virtual Event
11-12
Mar
San Francisco, CA
18-20
Mar
Savannah, GA
6-8
May
Jersey City, NJ

View all events